Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Pachl

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|August 13, 2010
[The relation between publication bias and clinical trials funding]Gisela Schott, Henry Pachl, Wolf-Dieter Ludwig
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 14, 2011
[Clinical trials in oncology: deficits and proposals for solution]Gisela Schott, Nicola Gökbuget, Henry Pachl, et al.
Deutsches Arzteblatt International|October 1, 2013
Does the pharmaceutical industry influence guidelines?: two examples from GermanyGisela Schott, Claudia Dünnweber, Bernd Mühlbauer, et al.
Deutsches Arzteblatt International|March 11, 2014
In replyGisela Schott, Henry Pachl, Wolf-Dieter Ludwig, et al.
Deutsches Arzteblatt International|May 22, 2010
The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publicationGisela Schott, Henry Pachl, Ulrich Limbach, et al.
Deutsches Arzteblatt International|May 15, 2010
The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trialsGisela Schott, Henry Pachl, Ulrich Limbach, et al.
Deutsches Arzteblatt International|July 25, 2015
Declaration and Handling of Conflicts of Interest in Guidelines: A Study of S1 Guidelines From German Specialist Societies From 2010-2013Gisela Schott, Klaus Lieb, Jochem König, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|August 13, 2010
[The relation between publication bias and clinical trials funding]Gisela Schott, Henry Pachl, Wolf-Dieter Ludwig
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 14, 2011
[Clinical trials in oncology: deficits and proposals for solution]Gisela Schott, Nicola Gökbuget, Henry Pachl, et al.
Deutsches Arzteblatt International|October 1, 2013
Does the pharmaceutical industry influence guidelines?: two examples from GermanyGisela Schott, Claudia Dünnweber, Bernd Mühlbauer, et al.
Deutsches Arzteblatt International|March 11, 2014
In replyGisela Schott, Henry Pachl, Wolf-Dieter Ludwig, et al.
Deutsches Arzteblatt International|May 22, 2010
The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publicationGisela Schott, Henry Pachl, Ulrich Limbach, et al.
Deutsches Arzteblatt International|May 15, 2010
The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trialsGisela Schott, Henry Pachl, Ulrich Limbach, et al.
Deutsches Arzteblatt International|July 25, 2015
Declaration and Handling of Conflicts of Interest in Guidelines: A Study of S1 Guidelines From German Specialist Societies From 2010-2013Gisela Schott, Klaus Lieb, Jochem König, et al.
Pageof 1